Sarah Mcwhirter

Sarah McWhirter, Ph.D. serves as Vice President, Head of Biology at Lycia Therapeutics. Prior to Lycia, she served as Executive Director of Research and Translational Medicine at Aduro Biotech. At Aduro, Sarah was promoted into roles of increasing responsibility where she was the primary R&D lead for the Novartis partnership developing STING agonists for oncology that led to a first-in-human STING agonist. She and her team also spearheaded discovery efforts that enabled a research collaboration and licensing agreement with Eli Lilly to develop therapeutics for autoimmune and inflammatory diseases. Prior to Aduro, Sarah supervised research activities in Dr. Mark Schlissel’s laboratory at University of California, Berkeley. Sarah earned her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley and conducted postdoctoral fellowship in at Harvard University in the laboratory of Dr. Tom Maniatis.